Home       Top Rated       Submit Article     Advanced Search     FAQ       Contact Us       Lawyers in India       Law Forum     RSS Feeds     

Register your Copyright Online

We offer copyright registration right from your desktop click here for details.

Latest Articles | Articles 2014 | Articles 2013 | Articles 2012 | Articles 2011 | Articles 2010 | Articles 2009 | Articles 2008 | Articles 2007 | Articles 2006 | Articles 2000-05

Search On:Laws in IndiaLawyers Search

Mutual Consent Divorce in Delhi
We provide fast, cost effective and Hassle free solution.
Contact us at Ph no: 9650499965 (Divorce Law Firm Delhi)
File Caveat in Supreme Court
Contact Ph no: +9650499965

Main Categories
 Accident Law
 Animal Laws
 Aviation Law
 Bangladesh Law
 Banking and Finance laws
 Case Laws
 Civil Laws
 Company Law
 Constitutional Law
 Consumer laws
 Contracts laws
 Criminal law
 Drug laws
 Dubai laws
 Educational laws
 Employment / Labour laws
 Environmental Law
 family law
 Gay laws and Third Gender
 Human Rights laws
 Immigration laws
 Insurance / Accident Claim
 Intellectual Property
 International Law
 Juvenile Laws
 Law - lawyers & legal Profession
 Legal Aid and Lok Adalat
 Legal outsourcing
 Media laws
 Medico legal
 Real estate laws
 Right To Information
 Tax Laws
 Torts Law
 Woman Issues
 Workplace Equality & Non-Discrimination
 Yet Another Category

More Options
 Most read articles
 Most rated articles

Subscribe now and receive free articles and updates instantly.


Published : September 08, 2016 | Author : PRASHANTI UPADHYAY
Category : Medico legal | Total Views : 963 | Unrated

Pashanti Upadhyay pursuing LL.M. from Law College Dehradun Uttaranchal University

Green Light on the New Veterinary Medicinal Products Legislation in the EU

Last June, the EU Parliament started discussions and issued amendments on the European Commission’s Proposals for two new Regulations. Alongside, the FVE (Federation of Veterinarians of Europe) issued their comments on the amendments of the two proposals made by the EU Parliament, in September 2015.

The first such amendment aims to repeal and replace the Directive 2001/82/EC (Veterinary Medicines Code). After long discussions and consultation by the interested stakeholders, the problems were spotted and the light of new measures was switched on: the current legislation is considered obsolete, does not reflect the scientific advancements in the sector, cannot combat the lack of availability of veterinary medicinal products in certain markets, does not contribute to the smooth functioning of the internal market, by imposing disproportionate administrative burdens and, as a result, hampers innovation.

To start with, the new secondary legislation applies the foundation principles of the primary EU law, regarding, firstly, the establishment and functioning of the internal market as well as the approximation of regulatory and administrative procedures (article 114, Treaty on the Functioning of the EU) and, secondly, the competence of European Union to take measures in order to ensure a high level of public health protection, particularly in the veterinary field according to the article 168 par 4 of the Treaty on the Functioning of the EU.

The main points of the upcoming legislation could be identified as such:

(1) The first significant point of the legislation is that only veterinary medicinal products which meet the standards of safety, quality, and efficacy, set by European Commission and after being authorized by the competent bodies can be placed on the market. The product can be marketed only for the approved indications and use, already included in the terms of marketing authorization. Stricter requirements are foreseen for medicines targeting at food producing animals. The applicants will have the burden to prove the quality, safety, and efficacy of the product by submitting the relevant data, with some exceptions foreseen, however, especially in emergency cases.

(2) In order to reduce packaging costs, the European Commission promotes the idea of one uniform package for all countries, the simplification and limitation of the necessary information and presents harmonized pictograms and abbreviations. Furthermore, the proposed harmonization of product characteristics aims to eradicate the divergences i) between the reference and the generic medicines within the same state or ii) between medicines in different countries.

(3) What is more, the proposal aims to facilitate the marketing authorization of generic products by reducing the documentation required by the competent agency.

(4) The European Commission, with the aim to give incentives to innovation, suggested the extension of the patent protection (from 10 years) by one year for any extension of one veterinary medicinal product to other species (up to a maximum of 18 years). Enhanced protection of 14 years will be also provided for the initial marketing authorization of medicines for minor species, instead of the basic 10-year period. Furthermore, the application for the extension shall be submitted three years prior to the expiry of the protection, which means that, just after the expiry, a generic product can be placed on the market.

(5) An important change constitutes the establishment of the unlimited validity of one authorization, which replaces the current system of renewals every 5 years.

(6) The centralized procedure, in the context of which the authorization is granted by the Commission, becomes optional for any other product, besides the mandatory procedure required for biotechnology products as well as veterinary medicinal products intended primarily for use as performance enhancers in order to promote growth of treated animals or to increase yields from treated animals. In this way, products shall be marketed in all Member States and the applicant will avoid the extra financial costs for national authorizations.

(7) In order to combat the urgent problem of antibiotic resistance, it has been foreseen that the Commission can restrict or exclude the use of certain antimicrobials in the veterinary sector. However, innovation shall also be reinforced in order to ensure that there are always new products in the pipeline to treat the diseases.

(8) In reference to the post-authorization period, only substantial changes to the safety and efficacy of the products will be subject to prior authorization. Moreover, the periodic safety update reports will no longer be obligatory. On the contrary, a risk-based approach is adopted. The Agency and the national authorities will cooperate to monitor and assess data on adverse events and decide on the actions required. In order to reinforce the traceability of the products and their properties, the Commission suggested the establishment of a central database for all authorized medicinal products which will be updated by national competent authorities.

(9) A new issue covered by the new legislation, which has caused heated debate among policy makers and stakeholders is the online sale of medicinal products. According to the proposal, this will be allowed for products already authorized in the Member state in which the buyer is established.

The new Regulation can be a significant opportunity to support innovation and the development of the European veterinary medicine industries, by ensuring extended intellectual property right protection and by reducing the financial cost of relevant investments. In the same direction, the harmonization of the requirements and the establishment of a common procedure will facilitate the industry functioning and the greater product availability, especially in smaller nation.


1 2 3 4 5
Rate this article!     Poor

Most viewed articles in Medico legal category
Medical Negligence in India
Organ Transplantation-Legal,Social and Ethical issues
Clinical Trial Regulation In India
Human Cloning and Ethics
Medical Negligence: A Specific Tort
Test of Medical Negligence
Health Care During Armed Conflict
Two-Finger Test an Impertinent Approach
Protection of Traditional Medicinal Knowledge
Medical Negligence
Pre-Conception and Pre-natal Diagnostic Techniques Act
Green Light on the New Veterinary Medicinal Products Legislation in the EU
Clinical Trials in Ayurvedic Drugs
Most recent articles in Medico legal category
Clinical Trials in Ayurvedic Drugs
Medical Negligence
Green Light on the New Veterinary Medicinal Products Legislation in the EU
Medical Negligence: A Specific Tort
Two-Finger Test an Impertinent Approach
Pre-Conception and Pre-natal Diagnostic Techniques Act
Test of Medical Negligence
Protection of Traditional Medicinal Knowledge
Human Cloning and Ethics
Medical Negligence in India
Clinical Trial Regulation In India
Health Care During Armed Conflict
Organ Transplantation-Legal,Social and Ethical issues

Article Comments

there are no comments...

Please login or register a new free account.

Random Pick
Autochthony is a word that rarely surfaces in everyday English, but it is a synonym for native or indigenous. It is most often used in anthropology, biology and related sciences, but is also used in law

» Total Articles
» Total Authors
» Total Views
» Total categories

Law Forum

Legal Articles

Lawyers in India- Click on a link below for legal Services

lawyers in Chennai
lawyers in Bangalore
lawyers in Hyderabad
lawyers in Cochin
lawyers in Pondicherry
lawyers in Guwahati
lawyers in Nashik

lawyers in Jaipur
lawyers in New Delhi
lawyers in Dimapur
lawyers in Agra
Noida lawyers
lawyers in Siliguri

For Mutual consent Divorce in Delhi

Ph no: 9650499965
For online Copyright Registration

Ph no: 9891244487
Law Articles

lawyers in Delhi
lawyers in Chandigarh
lawyers in Allahabad
lawyers in Lucknow
lawyers in Jodhpur
Faridabad lawyers

lawyers in Mumbai
lawyers in Pune
lawyers in Nagpur
lawyers in Ahmedabad
lawyers in Surat
Ghaziabad lawyers

lawyers in Kolkata
lawyers in Janjgir
lawyers in Rajkot
lawyers in Indore
lawyers in Ludhiana
Gurgaon lawyers


India's Most Trusted Online law library
Legal Services India is Copyrighted under the Registrar of Copyright Act ( Govt of India) 2000-2017
 ISBN No: 978-81-928510-1-3